A randomized, double-blind, placebo-controlled, multicenter phase II study to compare the efficacy and safety of sorafenib added to standard treatment with topotecan to standard treatment alone in patients with platinum-resistant recurrent ovarian cancer (TRIAS): Results of a NOGGO-AGO intergroup pilot-study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e15548-e15548
Author(s):  
K. El Khalfaoui ◽  
S. Mahner ◽  
R. Richter ◽  
F. Hilpert ◽  
R. Lorenz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Pilot Study ◽  
Phase Ii ◽  
Standard Treatment ◽  
Phase Ii Study ◽  
Recurrent Ovarian Cancer ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Multicenter Phase

A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5557-5557 ◽  
Author(s):  
Gottfried E. Konecny ◽  
Andrea Elisabeth Wahner Hendrickson ◽  
Aminah Jatoi ◽  
Jill K. Burton ◽  
Jill Paroly ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Ovarian Cancer ◽  
Efficacy And Safety ◽  
Open Label ◽  
Cyclin Dependent Kinases ◽  
Open Label Phase

scholarly journals A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

2014 ◽  
Vol 89 (7) ◽  
pp. 709-713 ◽  
Author(s):  
Marvin E. Reid ◽  
Amal El Beshlawy ◽  
Adlette Inati ◽  
Abdullah Kutlar ◽  
Miguel R. Abboud ◽  
...  
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Efficacy And Safety ◽  
Cell Disease ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document